Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar-Apr;130(2):143-52.
doi: 10.1177/003335491513000207.

Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001-2010

Jacques Baillargeon  1 , Randall J Urban  2 , Yong-Fang Kuo  3 , Holly M Holmes  4 , Mukaila A Raji  3 , Abraham Morgentaler  5 , Bret T Howrey  6 , Yu-Li Lin  7 , Kenneth J Ottenbacher  1
Affiliations

Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001-2010

Jacques Baillargeon et al. Public Health Rep. 2015 Mar-Apr.

Abstract

Objectives: The Endocrine Society recommends testosterone therapy only in men with low serum testosterone levels, consistent symptoms of hypogonadism, and no signs of prostate cancer. We assessed screening and monitoring patterns in men receiving testosterone therapy in the U.S.

Methods: We conducted a retrospective cohort study of 61,474 men aged ≥40 years, and with data available in one of the nation's largest commercial insurance databases, who received at least one prescription for testosterone therapy from 2001 to 2010.

Results: In the 12 months before initiating treatment, 73.4% of male testosterone users received a serum testosterone test and 60.7% received a prostate-specific antigen (PSA) test. Among men who were tested, 19.5% did not meet Endocrine Society guidelines for low testosterone. In the 12 months after initiating treatment, 52.4% received a serum testosterone test and 43.3% received a PSA test. Multivariable analyses showed that those seen by either an endocrinologist or urologist were more likely to receive appropriate tests.

Conclusions: A substantial number of men prescribed testosterone therapy did not receive testosterone or PSA testing before or after initiating treatment. In addition, almost one out of five treated men had baseline serum testosterone values above the threshold defined as normal by the Endocrine Society. Men treated by endocrinologists and urologists were more likely to have been treated according to guideline recommendations than men treated by other specialties, including primary care.

PubMed Disclaimer

Figures

Figure
Figure
Androgen medications, by drug and product names and HCPCS and NDC codes
Figure
Figure
Androgen medications, by drug and product names and HCPCS and NDC codes
See this image and copyright information in PMC

Comment in

References

    1. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001–2011 [published erratum appears in JAMA Intern Med 2013;173:1477] JAMA Intern Med. 2013;173:1465–6. - PMC - PubMed
    1. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone in healthy men: Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724–31. - PubMed
    1. Swerdloff RS, Wang C. Androgens and the ageing male. Best Pract Res Clin Endocrinol Metab. 2004;18:349–62. - PubMed
    1. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482–92. - PubMed
    1. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:29–39. - PubMed

Publication types